CVS Health Corp (CVS)
71.75
+1.49 (2.12%)
NYSE · Last Trade: Sep 10th, 3:19 AM EDT
Detailed Quote
Previous Close | 70.26 |
---|---|
Open | 71.56 |
Bid | 71.51 |
Ask | 71.98 |
Day's Range | 70.72 - 73.05 |
52 Week Range | 43.56 - 74.53 |
Volume | 10,585,492 |
Market Cap | 94.68B |
PE Ratio (TTM) | 19.99 |
EPS (TTM) | 3.6 |
Dividend & Yield | 2.660 (3.71%) |
1 Month Average Volume | 6,607,837 |
Chart
About CVS Health Corp (CVS)
CVS Health Corp is a diversified healthcare company that operates a vast network of retail pharmacies, providing prescription medications, over-the-counter products, and health and wellness services. In addition to its retail operations, CVS Health also offers pharmacy benefit management services, helping manage prescription drug costs for businesses and health plans. The company is involved in providing health insurance and health services through its various divisions, including a growing presence in digital health solutions and immunization services. By integrating pharmacy services with healthcare delivery, CVS Health aims to enhance patient care and improve health outcomes across the communities it serves. Read More
News & Press Releases
Shares of diversified healthcare company CVS Health (NYSE:CVS)
jumped 2.9% in the afternoon session after broad positive sentiment in the healthcare sector was supported by a bullish analyst outlook.
Via StockStory · September 9, 2025
CVS Health Corporation reverses off of support around the $70 level. There is support at this level because it was resistance.
Via Benzinga · September 9, 2025
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Via StockStory · September 9, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Oscar Health (NYSE:OSCR) and the best and worst performers in the health insurance providers industry.
Via StockStory · September 8, 2025
Shares of diversified healthcare company CVS Health (NYSE:CVS)
fell 4.8% in the afternoon session after two Republican congressmen launched an investigation into the company over concerns it may have violated the HIPAA privacy law.
Via StockStory · September 8, 2025
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
Via Chartmill · September 8, 2025
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · September 8, 2025
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
Via Benzinga · September 8, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Via StockStory · September 4, 2025
As the financial world braces for the highly anticipated Federal Open Market Committee (FOMC) meeting on September 16-17, 2025, market participants are largely anticipating a significant shift in monetary policy. The strong likelihood of a 25-basis-point interest rate cut by the Federal Reserve is now a central focus, promising to
Via MarketMinute · September 3, 2025
Are markets open on Labor Day 2025? Learn what's open and closed on Sept 1, from stocks to stores. Plan your holiday with our guide!
Via Benzinga · September 1, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Clover Health (NASDAQ:CLOV).
Via StockStory · August 27, 2025
BENSALEM, Pa. - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today the successful closing of Bensalem Crossings, a 67,215-square-foot grocery- and drug-anchored shopping center in the Philadelphia metro. The property sold for $12.45 million to a private investor based in California.
Via AB Newswire · August 27, 2025
The ultimate long-term investing strategy is buying stocks and holding them forever.
Via The Motley Fool · August 27, 2025
Walgreens Boots Alliance shares slipped slightly on Tuesday as investors adjusted positions ahead of its planned private equity deal.
Via The Motley Fool · August 26, 2025
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon.
Via Benzinga · August 26, 2025
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Via StockStory · August 26, 2025
These low-risk stocks can provide you with reliable and steadily growing passive income.
Via The Motley Fool · August 26, 2025
The drug is soon to launch in Europe with a new name and a big potential market.
Via Investor's Business Daily · August 26, 2025
A wave of innovation is surging through the small-cap markets, with technology, biotech, and energy players making headlines across key growth sectors. From unmanned aircraft battery systems and AI robotics, healthcare, to telecom profitability and sustainable recycling and more, these companies are positioning themselves as disruptive leaders in their fields.
Via AB Newswire · August 22, 2025
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
Via Benzinga · August 21, 2025
Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug.
Via Investor's Business Daily · August 21, 2025
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
Via Benzinga · August 21, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Humana (NYSE:HUM).
Via StockStory · August 20, 2025